Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score

被引:29
|
作者
Tuomilehto, Jaakko [1 ,2 ,3 ]
Lindstrom, Jaana [1 ,2 ]
Hellmich, Martin [4 ]
Lehmacher, Walter [4 ]
Westermeier, Torsten [5 ]
Evers, Thomas [5 ]
Brueckner, Andreas [6 ]
Peltonen, Markku [2 ]
Qiao, Qing [1 ]
Chiasson, Jean-Louis [7 ]
机构
[1] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland
[2] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Diabet Prevent Unit, Helsinki, Finland
[3] S Ostrobothnia Cent Hosp, Seinajoki, Finland
[4] Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany
[5] Bayer Vital GmbH, Leverkusen, Germany
[6] Bayer HealthCare, Wuppertal, Germany
[7] Univ Montreal, Ctr Hosp, Res Ctr, Res Grp Diabet & Metab Regulat, Montreal, PQ H3C 3J7, Canada
关键词
Risk-score; Type; 2; diabetes; Glucose tolerance; LIFE-STYLE INTERVENTION; CARDIOVASCULAR-DISEASE; IDENTIFYING INDIVIDUALS; FOLLOW-UP; PREDICTION; POPULATION; QUESTIONNAIRE; PERFORMANCE; PREVENTION; ACARBOSE;
D O I
10.1016/j.diabres.2009.11.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To develop a risk-score model, based on available clinical data to assess absolute risk of type 2 diabetes among people with impaired glucose tolerance (IGT). Methods: Data from the study to prevent non-insulin dependent diabetes mellitus (STOP-NIDDM) investigating acarbose treatment in individuals with IGT were used to develop multivariable Cox proportional hazards model for the time to onset of diabetes. The final model equation was externally validated using data from the Finnish Cardiovascular Risk Factor (FINRISK) population. Results: The risk-score model included the variables acarbose treatment, gender, serum triglyceride level, waist circumference, fasting plasma glucose, height, history of cardiovascular disease (CVD) and hypertension. The final model yielded an area under the receiver-operating-characteristic curve (AUC(ROC)) of 0.64 when applied to people with IGT in the STOP-NIDDM, and 0.84 and 0.90 when applied to FINRISK population with IGT alone and IGT and normal glucose tolerance combined, respectively; AUC(ROC) is a measure of the discriminatory power of the model (1, perfect discrimination). Conclusions: The STOP-NIDDM risk-score is a simple and validated tool that can identify high-risk individuals with IGT who would benefit most from type 2 diabetes or CVD prevention strategies, such as lifestyle management or early acarbose treatment. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 50 条
  • [1] Development and Validation of a Risk-Score Model for Type 2 Diabetes: A Cohort Study of a Rural Adult Chinese Population
    Zhang, Ming
    Zhang, Hongyan
    Wang, Chongjian
    Ren, Yongcheng
    Wang, Bingyuan
    Zhang, Lu
    Yang, Xiangyu
    Zhao, Yang
    Han, Chengyi
    Pang, Chao
    Yin, Lei
    Xue, Yuan
    Zhao, Jingzhi
    Hu, Dongsheng
    [J]. PLOS ONE, 2016, 11 (04):
  • [2] Development and validation of a risk-score model for opioid overdose using a national claims database
    Heo, Kyu-Nam
    Lee, Ju-Yeun
    Ah, Young-Mi
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [3] Development and validation of a risk-score model for opioid overdose using a national claims database
    Kyu-Nam Heo
    Ju-yeun Lee
    Young-Mi Ah
    [J]. Scientific Reports, 12
  • [4] Skin autofluorescence is additive to the UKPDS risk-score in the prediction of cardiovascular complications in type 2 diabetes
    Lutgers, Helen L.
    Gerrits, Esther G.
    Bilo, Henk J.
    Smit, Andries J.
    [J]. DIABETES, 2007, 56 : A173 - A174
  • [5] The development and validation of the Portuguese risk score for detecting type 2 diabetes and impaired fasting glucose
    Gray, Laura J.
    Barros, Henrique
    Raposo, Luis
    Khunti, Kamlesh
    Davies, Melanie J.
    Santos, Ana Cristina
    [J]. PRIMARY CARE DIABETES, 2013, 7 (01) : 11 - 18
  • [6] Simple risk factors for developing type 2 diabetes mellitus as identified in the STOP-NIDDM trial
    Tuomilehto, J.
    Peltonen, M.
    Qiao, Q.
    Chiasson, J. -L.
    Hellmich, M.
    Lehmacher, W.
    Evers, T.
    [J]. DIABETOLOGIA, 2006, 49 : 439 - 440
  • [7] A risk-score model for predicting risk of type 2 diabetes mellitus in a rural Chinese adult population: A cohort study with a 6-year follow-up
    Zhang, Hongyan
    Wang, Chongjian
    Ren, Yongcheng
    Wang, Bingyuan
    Yang, Xiangyu
    Zhao, Yang
    Han, Chengyi
    Zhou, Junmei
    Zhang, Lu
    Qi, Minjie
    Zhai, Yujia
    Pang, Chao
    Yin, Lei
    Zhao, Jingzhi
    Hu, Dongsheng
    Zhang, Ming
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (07)
  • [8] Acarbose reduces incidence of type 2 diabetes and of myocardial infarction in subjects with impaired glucose tolerance: The STOP-NIDDM trial
    Hanefeld, M
    Temelkova-Kurktschiev, TTK
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 : 609 - 609
  • [9] Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial
    Hanefeld, Markolf
    Karasik, Avraham
    Koehler, Carsta
    Westermeier, Torsten
    Chiasson, Jean-Louis
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2009, 6 (01): : 32 - 37
  • [10] Acarbose can prevent Type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: The STOP-NIDDM trial
    Chiasson, J
    Josse, RG
    Gomis, R
    Hanefeld, M
    Karasik, A
    Laakso, M
    [J]. DIABETOLOGIA, 2002, 45 : A104 - A104